The Epoch Times The first patient in a clinical trial analyzing Pfizer’s oral COVID-19 drug has received the first dose of the medication, the company announced on Sept. 1.
The study is analyzing a protease inhibitor known as PF-07321332. The drug is meant to combat COVID-19 in patients who experience symptoms from the disease, but don’t require hospital care.
The randomized, double-blind trial will enroll about 1,140 participants, approximately half of whom will receive a placebo. The participants will receive the drug or the placebo every 12 hours orally for five days.
Daily News PDF Archives – Jellyfish.News